The bioartificial kidney in the treatment of acute kidney injury

Current Drug Targets

Volumn 10, Issue 12, 2009, Pages 1227-1234

  Song, Joon Ho ^a   Humes, H David ^b  

^a Inha University School of Medicine   (South Korea)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acute kidney injury; Bioartificial kidney; Cell therapy; Renal replacement therapy; Systemic inflammatory response syndrome

Indexed keywords

NITROGEN; UREA;

ACUTE KIDNEY FAILURE; ASSISTIVE TECHNOLOGY DEVICE; BIOARTIFICIAL KIDNEY; BIOARTIFICIAL ORGAN; CATABOLISM; CELL THERAPY; CELL VIABILITY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; ELECTROLYTE BALANCE; ENDOCRINE FUNCTION; FLUID BALANCE; GLOMERULUS FILTRATION; HEART PERFORMANCE; HEMODIALYSIS; HEMODYNAMICS; HORMONE RELEASE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; KIDNEY CELL; KIDNEY FUNCTION; MULTIPLE ORGAN FAILURE; RENAL REPLACEMENT THERAPY; REVIEW; SAFETY; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANIMALS; BIOARTIFICIAL ORGANS; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES; KIDNEY, ARTIFICIAL; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 72849129955     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789753273     Document Type: Review

References (51)

1. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104: 343-348
2. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693 (Pubitemid 32221925)
3. Humes HD, MacKay SM, Funke AJ, Buffington DA. Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. Kidney Int 1999; 55: 2502-2514
4. Stadnyk AW. Cytokine production in epithelial cells. FASEB J 1994; 8: 1041-1047
5. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257: L163-73.
6. Tannen RL, Sastrasinh S. Response of ammonia metabolism to acute acidosis. Kidney Int 1984; 25: 1-10. (Pubitemid 14159379)
7. Maack T. Renal handling of proteins and polypeptides. In: Windhager EE, Ed. Handbook of Physiology. New York: Oxford University Press 1992, pp. 2039-2118
8. Bishop GA, Waugh JA, Hall BM. Expression of HLA antigens on renal tubular cell stimulation of lymphocyte activation and on their vulnerability to cell-mediated lysis. Transplantation 1988; 46: 303-310
9. Wahl P, Schoop R, Bilic G, Neuweiler J, Le Hir M, Yoshinaga SK, et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (Inducible Costimulator Ligand). J Am Soc Nephrol 2002; 13: 1517-1526
10. Prodjosudjadi W, Gerritsma JS, Klar-Mohamed N, Gerritsen AF, Bruijn JA, Daha MR, et al. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 1995; 48: 1477-1486
11. Humes HD. Bioartificial kidney for full renal replacement therapy. Semin Nephol 2000; 20: 71-82.
12. Kelly KJ. Acute renal failure: Much more than a kidney disease. Semin Nephrol 2006; 26: 105-113
13. Breen D, Bihari D. Acute renal failure as a part of multiple organ failure: The slippery slope of critical illness. Kidney Int 1998; 53(Suppl66): S25-33.
14. Humes HD, MacKay SM, Funke AJ, Buffington DA. The bioartificial renal tubule assist device to enhance CRRT in acute renal failure. Am J Kidney Dis 1997; 30(Suppl): S28-31.
15. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-138 (Pubitemid 34701986)
16. Humes HD, MacKay SM, Funke AJ, Buffington DA. Acute renal failure: Growth factors, cell therapy, gene therapy. Proc Assoc Am Phys 1997; 109: 547-557
17. Bellomo R. Do we know the optimal dose for renal replacement therapy in the intensive care unit? Kidney Int 2005; 70: 1202-2120
18. Pannu N, Klarenbach S, Wiebe N. Renal replacement therapy in patients with acute renal failure: A systematic review. JAMA 2008; 299: 793-805. (Pubitemid 351281573)
19. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. VA/NIH Acute Renal Failure Trial Network: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20.
20. Bone RC, Grodzin CJ, Balk RA. Sepsis. A new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-243
21. Gage FH. Cell therapy. Nature 1998; 392: 518-524
22. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260: 920-926
23. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: A phase I clinical trial. Ann Surg 1997; 225: 484-494
24. Nikolovski J, Gulari E, Humes HD. Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant 1999; 8: 351-364 (Pubitemid 29409602)
25. MacKay SM, Funke AJ, Buffington DA, Humes HD. Tissue engineering of a bioartificial renal tubule. ASAIO J 1998; 44: 179-183
26. Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel W. Replacement of renal function in uremic animals with a tissueengineered kidney. Nat Biotechnol 1999; 17: 451-455 (Pubitemid 29217896)
27. Humes HD, Fissell WH, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, et al. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 2002; 39: 1078-1087
28. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 2002; 20: 55-60.
29. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517-518
30. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 2003; 348: 255-256
31. Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD. Bioartificial kidney ameliorates gram negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003; 14: 454-461 (Pubitemid 36150870)
32. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, et al. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 2003; 31: 2421-2428
33. Le Tissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus. Nature 1997; 389: 681-682 (Pubitemid 27458943)
34. Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999; 285: 1236-1241
35. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66: 1578-1588
36. Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19: 1034-1040
37. Lally K, Cruz E, Xue H. The role of anti-tumor necrosis factor-α and interleukin-10 in protecting murine neonates from Escherichia coli sepsis. J Pediatr Surg 2000; 35: 852-854
38. Walley K, Lukacs N, Standiford T, Streiter R, Kunkel S. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64: 4733-4738
39. Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, et al. Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1998; 42: 2853-2857
40. Marchant A, Bruyns C, Vandenabeele P, Ducarne M, Gerard C, Delvaux A, et al. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24: 1167-1171 (Pubitemid 24132252)
41. Kielar M, Jeyarajah DR, Lu CY. The regulation of ischemic acute renal failure by extrarenal organs. Curr Opin Nephrol Hypertens 2002; 11: 451-457 (Pubitemid 34734626)
42. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Chest 1993; 103: 565-576
43. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-469
44. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24: 2699-2705
45. Redmond HP, Chavin KD, Bromberg JS, Daly JM. Inhibition of macrophase-activating cytokines is beneficial in the acute septic response. Ann Surg 1991; 214: 502-508
46. +NKT cells in lipopolysaccharide-induced lethal shock in mice. J Immunol 2002; 169: 1426-1432
47. Humes HD, Buffington DA, Lou L, Wang M, Abrishami S. Renal cell therapy ameliorates pulmonary abnormalities in a large animal model of septic shock and acute renal injury. J Am Soc Nephrol 2007; 18: A382.
48. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365 (Pubitemid 38406974)
49. Maroszynska I, Fiedor P. Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury. Ann Transplant 2000; 5: 5-11.
50. Ding F, Song JH, Lou L, Rojas A, Reoma JL, Cook KE, et al. A novel selective cytopheretic inhibitory device (SCD) inhibits circulating leukocyte activation and ameliorates multiorgan dysfunction in a porcine model of septic shock. (Abstract.) J Am Soc Nephrol 2008; 19: 458A.
51. Humes HD, Dillon J, Tolwani A, Cremisi H, Wali R, Murray P, et al. A novel selective cytopheretic inhibitory device (SCD) improves mortality in ICU patients with acute kidney injury (AKI) and multiorgan failure (MOF) in a phase II clinical study. (Abstract.) J Am Soc Nephrol 2008; 19: 458A.